Michael Makris Shares French Regulatory Update: Marstacimab (Hympavzi) Not Recommended for Severe Haemophilia A or B
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, shared a post on Linkedin:
“Interesting development from France. The French authorities assessed marstacimab (Hympavzi) and concluded that it has no place in the therapeutic strategy for severe haemophilia A or B without inhibitors.
They questioned the robustness of the comparative assessment against other approved therapies and pointed to uncertainties in terms of safety.
The document is in French but Google translate does a pretty good job if you do not speak French. I attach the Google translate version of the conclusion. ”
Check out here for more.
Find more posts on Hemostasis Today.
-
Jul 23, 2026, 09:05Fonkou Steve: What If We’ve Been Asking the Wrong Question About Plasma Too?
-
Jul 23, 2026, 08:27Registration Is Now Open for ASH 2026
-
Jul 23, 2026, 08:19Sheeza Nawaz: Why Do Patients With Aortic Stenosis Bleed?
-
Jul 23, 2026, 07:59Paschalis Karakasis: Can Left Atrial Appendage Closure Truly Replace Oral Anticoagulation?
-
Jul 23, 2026, 06:53Lakmali Silva: What Makes ISTH More Than a Scientific Meeting?
-
Jul 23, 2026, 05:48Paschalis Evangelidis: Rethinking Pulmonary Embolism Through the Lens of Thromboinflammation
-
Jul 23, 2026, 05:35Neil Morgan: Honoured to Lead the Platelet and Megakaryocyte Theme at ISTH 2026
-
Jul 23, 2026, 04:42Camilla Oriani: A Memorable First ISTH 2026 in Paris
-
Jul 23, 2026, 03:32Nazlı Pelin Kirkayak: A 9-Year Real-World Analysis of Adult Thrombotic Microangiopathies